EODData

MEMBERSHIP REGISTER LOG IN

NASDAQ, APVO:

19 Sep 2025
LAST:

1.760

CHANGE:
 0.22		OPEN:
1.890		HIGH:
1.990		ASK:
2.880		VOLUME:
6.38M
CHG(%):
11.11		PREV:
1.980		LOW:
1.750		BID:
2.040		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
19 Sep 251.8901.9901.7501.7606.38M
18 Sep 252.5102.5501.7701.980115.35M
17 Sep 251.5301.5301.3201.41013.25M
16 Sep 252.2002.7101.4201.500114.37M
15 Sep 251.5001.5201.4001.440218.4K
12 Sep 251.5101.5421.4301.470256.3K
11 Sep 251.5301.5401.4601.500220.1K
10 Sep 251.5201.5581.4601.500278.2K
09 Sep 251.5301.5841.4801.530239.5K
08 Sep 251.5901.6001.4801.480258.5K

COMPANY PROFILE

Name:
About:Aptevo Therapeutics Inc., a clinical-stage research and development biotechnology company, focuses on developing immunotherapeutic candidates for the treatment of various forms of cancer in the United States. The company develops its products using ADAPTIR and ADAPTIR-FLEX platforms to generate monospecific, bispecific, and multi-specific antibody candidates capable of enhancing the human immune system against cancer cells. Its lead clinical blood cancer candidate is mipletamig that is in Phase 1b/2 clinical trial for the treatment of acute myelogenous leukemia. The company also develops ALG.APV-527, a novel investigational bispecific ADAPTIR candidate that is in Phase 1 clinical trial for the treatment of non-small cell lung cancer, head and neck, colorectal, pancreatic, breast, and other solid tumors; APVO603, a preclinical dual agonist bispecific ADAPTIR candidate to treat multiple solid tumors; APVO442, a preclinical bispecific candidate based on the ADAPTIR-FLEX platform technology for the treatment of multiple solid tumors; and APVO711, a preclinical dual mechanism bispecific ADAPTIR candidate to treat prostate cancer. It has a collaboration and option agreement with Alligator Bioscience AB to develop ALG.APV-527. Aptevo Therapeutics Inc. was incorporated in 2016 and is headquartered in Seattle, Washington.
Sector:Healthcare
Industry:Biotechnology
Address:2401 4th Avenue, Seattle, WA, United States, 98121
Website:https://aptevotherapeutics.com
CUSIP:03835L207
CIK:0001671584
ISIN:US03835L2079
FIGI:BBG009RRZ8C2
LEI:529900UTQOXOZBMZFN24

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

P/E Ratio:0.00
Price to Book:1.00
Price to Sales:1.61
Shares:3.29M
Market Cap:5.79M

TECHNICAL INDICATORS

MA5:1.62
MA10:1.56
MA20:1.65
MA50:2.21
MA100:2.45
MA200:2.97
STO9:26.92
STO14:26.92
RSI14:54.23
WPR14:-38.60
MTM14:0.16
ROC14:0.10
ATR:0.28
Week High:2.71
Week Low:1.32
Month High:2.71
Month Low:1.32
Year High:14.90
Year Low:0.14
Volatility:42.43

RECENT SPLITS

Date Ratio
27 May 20251-20
04 Dec 20241-37
06 Mar 20241-44
27 Mar 20201-14